Chong Kun Dang, Dong-A ST to launch Nesp biosimilars in Japan in H2 - (The Korea Herald via NewsPoints Desk)

  • South Korean biopharmaceutical companies Chong Kun Dang andDong-A ST plan to launch their biosimilars in Japan without a headwind, despite escalating trade strife, as their drugs will be represented by Japanese partner firms, reported The Korea Herald.

  • Both firms applied last October for their respective biosimilars of the erythropoietin drug Nesp, which is marketed by Amgen and Kyowa Hakko Kirin, and are awaiting the launch of sales in the second half of this year through their partner firms. According to the news source, the worldwide market for Nesp is estimated to be over $3 billion.

  • Chong Kun Dang and Dong-A ST believe that the pending approval from the Japanese Ministry of Health, Labor and Welfare's Pharmaceuticals and Medical Devices Agency will not be involved in the trade dispute involving Tokyo's restrictions against tech materials exported to Korea.

  • Dong-A ST licensed out DA-3880 to Japan's Sanwa Kagaku Kenkyusho in 2014, with the latter firm applying for DA-3880's approval in October last year.

  • "The application for approval was made through our Japanese partner, and therefore our concerns that the trade tension will affect the drug [are] low," commented a Dong-A ST representative.

  • Meanwhile, another Korean firm, CJ Healthcare, is also carrying out Phase III testing for its Nesp biosimilar CJ-40001 through Japanese partner YL Biologics, to which it licensed in 2017, the news source said.

To read more NewsPoints articles, click here.